The nation of Zimbabwe has turned down a substantial American health deal worth $367m (£272m) spanning five years due to the United States' request for sensitive biological samples.
This rejection came to light following a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
An official spokesman has since clarified that the United States was seeking genetic material for research and profit while refused to share the benefits from future vaccines.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further negotiations to find a agreement acceptable to both sides so the nation's vital HIV treatment initiative can proceed.
Broader Context
This development follows a similar case in Kenya, where a high court halted a similar deal with the US after legal challenges were filed about the security of Kenyans' health data.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost transparency and accountability.
According to statements, 16 African countries have to date signed similar agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our nation would provide the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our population if a future pandemic arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures already established via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This system is intended to ensure that when a nation contributes its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to further dialogue with our US partners on how future collaboration could be structured in a way that respects the sovereignty and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but recommended that talks need to persist considering a large portion of the country's HIV programmes were funded by foreign aid.
"If technical issues arise, including those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group said.
The halted deal emphasises the complex debate between receiving vital foreign assistance and protecting local interests in an increasingly data-driven world.